Autres langues Toleranzia AB

Actions

TOL

SE0007438577

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 16/07/2024			Varia. 5j.	Varia. 1 janv.
0,598 ^SEK	-0,33 %		-2,61 %	+39,72 %

31/05	Toleranzia AB (publ) mène avec succès une étude d'innocuité du TOL2 dans des échantillons de sang de patients atteints de myasthénie grave	CI
20/05	Toleranzia AB publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Announcement from the 2024 Annual General Meeting of Toleranzia AB (publ)	19/06
Toleranzia AB conducts successful safety study of TOL2 in blood samples from patients with myasthenia gravis	31/05
Toleranzia AB Conducts Successful Safety Study of TOL2 in Blood Samples from Patients with Myasthenia gravis	31/05
Toleranzia : Annual General Meeting 2024 06 19 – Postal voting form	28/05
Toleranzia : Annual General Meeting 2024 06 19 – Proxy form	28/05
Toleranzia : Annual General Meeting 2024 06 19 – Annual Report 2023	28/05
Toleranzia : Annual General Meeting 2024 06 19 – Auditor’s Report 2023	28/05
Notice of Annual General Meeting in Toleranzia AB (publ)	20/05
Toleranzia AB: Interim report first quarter 2024	20/05
Toleranzia AB Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05
Toleranzia AB: Annual report for the financial year 2023	30/04
Toleranzia AB receives loan commitment of SEK 20 million	24/04
Toleranzia reports positive outcome from advisory meeting with the German Medicines Agency for the TOL2 development program	18/03
Toleranzia AB – Year-End Report 2023	23/02
Toleranzia AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Toleranzia AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Toleranzia successfully completes GLP toxicology study of TOL2	15/01
Toleranzia AB Successfully Completes GLP Toxicology Study of TOL2	15/01
Toleranzia AB starts production of finished drug product for clinical studies	21/12
Toleranzia AB Starts Production of Completed Drug Product for Clinical Studies	21/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Toleranzia AB

Actions

TOL

SE0007438577

Autres langues

Filtres